Cargando…

Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment

BACKGROUND: While studies of HIV-infected adults on antiretroviral treatment (ART) report no sex differences in immune recovery and virologic response but more ART-associated complications in women, sex differences in disease progression and response to ART among children have not been well assessed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shiau, Stephanie, Kuhn, Louise, Strehlau, Renate, Martens, Leigh, McIlleron, Helen, Meredith, Sandra, Wiesner, Lubbe, Coovadia, Ashraf, Abrams, Elaine J, Arpadi, Stephen M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3927631/ https://www.ncbi.nlm.nih.gov/pubmed/24521425 http://dx.doi.org/10.1186/1471-2431-14-39

Ejemplares similares

Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir
por: Moultrie, Harry, et al.
Publicado: (2015)

Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir
por: Rabie, Helena, et al.
Publicado: (2020)

Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy
por: Naiker, Suhashni, et al.
Publicado: (2014)

Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children
por: Zhang, C, et al.
Publicado: (2010)

Comparative efficacy and safety of regimens including ritonavir-boosted lopinavir or nevirapine in antiretroviral-naïve HIV-1-infected individuals
por: Pereira, A, et al.
Publicado: (2010)

The Frequency of Malaria Is Similar among Women Receiving either Lopinavir/Ritonavir or Nevirapine-based Antiretroviral Treatment
por: Skinner-Adams, Tina S., et al.
Publicado: (2012)

Inadequate Lopinavir Concentrations With Modified 8-Hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV
por: Chabala, Chishala, et al.
Publicado: (2023)

Decreased bone turnover in HIV-infected children on antiretroviral therapy
por: Shiau, Stephanie, et al.
Publicado: (2018)

The Safety, Effectiveness and Concentrations of Adjusted Lopinavir/Ritonavir in HIV-Infected Adults on Rifampicin-Based Antitubercular Therapy
por: Decloedt, Eric H., et al.
Publicado: (2012)

Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ART
por: Rawizza, Holly E, et al.
Publicado: (2020)

First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting
por: Clumeck, Nathan, et al.
Publicado: (2014)

Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children
por: Bienczak, Andrzej, et al.
Publicado: (2017)

Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy
por: Banda, Clifford G., et al.
Publicado: (2018)

Distinct epigenetic profiles in children with perinatally-acquired HIV on antiretroviral therapy
por: Shiau, Stephanie, et al.
Publicado: (2019)

Nevirapine- Versus Lopinavir/Ritonavir-Based Initial Therapy for HIV-1 Infection among Women in Africa: A Randomized Trial
por: Lockman, Shahin, et al.
Publicado: (2012)

Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19
por: Klement-Frutos, Elise, et al.
Publicado: (2021)

Comparison of quantitative ultrasonography and dual X-ray absorptiometry for bone status assessment in South African children living with HIV
por: Roberts, Jackson A., et al.
Publicado: (2022)

Comparing albuvirtide plus ritonavir-boosted lopinavir regimen to two nucleotide reverse transcriptase inhibitors plus ritonavir-boosted lopinavir in HIV-infected individuals who failed initial treatment: a retrospective comparative cohort study
por: Chen, Liyu, et al.
Publicado: (2022)

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review
por: Chandwani, Ashish, et al.
Publicado: (2008)

Early antiretroviral treatment of infants to attain HIV remission
por: Kuhn, Louise, et al.
Publicado: (2020)

Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults
por: Rattanapunya, Siwalee, et al.
Publicado: (2015)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)

Evaluation of submaximal endurance in young children living with HIV
por: Potterton, Joanne, et al.
Publicado: (2022)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

Age at antiretroviral therapy initiation and cell-associated HIV-1 DNA levels in HIV-1-infected children
por: Kuhn, Louise, et al.
Publicado: (2018)

The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study
por: De Nicolò, Amedeo, et al.
Publicado: (2022)

Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children
por: Martinez, Beatriz Larru, et al.
Publicado: (2010)

A severe COVID-19 despite ongoing treatment with Lopinavir-Ritonavir
por: Joumaa, H., et al.
Publicado: (2020)

The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients
por: Kredo, T., et al.
Publicado: (2016)

Propofol/lopinavir/ritonavir: Bradyarrythmia: case report
Publicado: (2020)

Potential drug–drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir()
por: Brandariz-Nuñez, David, et al.
Publicado: (2020)

Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment
por: Magro, Paola, et al.
Publicado: (2021)

An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
por: Laker, Eva Agnes Odongpiny, et al.
Publicado: (2019)

Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure
por: Manosuthi, Weerawat, et al.
Publicado: (2012)

Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure
por: Manosuthi, Weerawat, et al.
Publicado: (2009)

Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
por: Broder, MS, et al.
Publicado: (2010)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
por: Ceccaldi, Pierre-François, et al.
Publicado: (2010)

Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
por: Alvarez, Jean Claude, et al.
Publicado: (2020)

Lopinavir/ritonavir: vomiting and watery diarrhoea: case report
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_iv930io1qaeqi3mqjjui7coml5